Desferal (deferoxamine) — Competitive Intelligence Brief

Desferal (deferoxamine) (Desferal (deferoxamine)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Iron chelator. Area: Hematology.

marketed Iron chelator Ferric iron (Fe³⁺) and ferrous iron (Fe²⁺) Hematology Small molecule

Target snapshot

Desferal (deferoxamine) (Desferal (deferoxamine)) — ApoPharma. Deferoxamine is an iron chelator that binds free iron in the body and facilitates its excretion through urine and feces.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Desferal (deferoxamine) TARGET	Desferal (deferoxamine)	ApoPharma	marketed	Iron chelator	Ferric iron (Fe³⁺) and ferrous iron (Fe²⁺)
Ferriprox	DEFERIPRONE	Chiesi	marketed	Iron Chelator [EPC]	Deoxyhypusine hydroxylase	2011-01-01
Exjade	DEFERASIROX	Novartis	marketed	Iron Chelator [EPC]	Flavin reductase (NADPH)	2005-01-01
Desferal	DEFEROXAMINE	Mitem Pharma	marketed	Iron Chelator	Deoxyhypusine hydroxylase	1968-01-01
deferiprone matching placebo tablets	deferiprone matching placebo tablets	ApoPharma	marketed	Iron chelator	Ferric iron (Fe³⁺)
Captafer®	Captafer®	American University of Beirut Medical Center	marketed	Iron chelator	Ferric iron (Fe³⁺)
Deferiprone (DFP)	Deferiprone (DFP)	Azienda Ospedaliera V. Cervello	marketed	Iron chelator	Ferric iron (Fe³⁺)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Iron chelator class)

1. ApoPharma · 3 drugs in this class
2. Consorzio per Valutazioni Biologiche e Farmacologiche · 2 drugs in this class
3. American University of Beirut Medical Center · 1 drug in this class
4. Azienda Ospedaliera V. Cervello · 1 drug in this class
5. CorMedix · 1 drug in this class
6. The George Institute · 1 drug in this class